CURX

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Curanex Pharmaceuticals Inc Common Stock

NASDAQ | CURX

0.50

USD

$0.00

(

0.00%

)

At Close (As of Nov 18, 2025)

$14.71M

Market Cap

-

P/E Ratio

-0.02

EPS

$9.18

52 Week High

$0.48

52 Week Low

HEALTHCARE

Sector

CURX Chart

Recent Chart
Price Action

CURX Technicals

Tags:

CURX Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$365K
Selling General And Administrative $290K
Research And Development -
Operating Expenses $365K
Investment Income Net -
Net Interest Income -
Interest Income -
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization -
Income Before Tax -$362K
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$362K
Comprehensive Income Net Of Tax -
Ebit -
Ebitda -$290K
Net Income -$362K

Revenue & Profitability

Earnings Performance

CURX Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $518K
Total Current Assets $518K
Cash And Cash Equivalents At Carrying Value $149K
Cash And Short Term Investments $149K
Inventory -
Current Net Receivables -
Total Non Current Assets $0
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $369K
Other Non Current Assets -
Total Liabilities $15K
Total Current Liabilities $15K
Current Accounts Payable $5K
Deferred Revenue -
Current Debt -
Short Term Debt -
Total Non Current Liabilities $0
Capital Lease Obligations -
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total -
Other Current Liabilities $9.6K
Other Non Current Liabilities -
Total Shareholder Equity $503K
Treasury Stock -
Retained Earnings -$622K
Common Stock $2.4K
Common Stock Shares Outstanding $28M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$556K
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $0
Capital Expenditures $5
Change In Receivables -
Change In Inventory $0
Profit Loss -
Cashflow From Investment -
Cashflow From Financing $630K
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$362K

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$365K
Selling General And Administrative $290K
Research And Development -
Operating Expenses $365K
Investment Income Net -
Net Interest Income -
Interest Income -
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization -
Income Before Tax -$362K
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$362K
Comprehensive Income Net Of Tax -
Ebit -
Ebitda -$290K
Net Income -$362K

CURX News

CURX Profile

Curanex Pharmaceuticals Inc Common Stock Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Curanex Pharmaceuticals Inc. is an innovative, developmental stage pharmaceutical company headquartered in Jericho, New York, specializing in the discovery and commercialization of botanical drugs for inflammatory diseases. The company is dedicated to enhancing patient quality of life through the development of novel therapeutic alternatives that address unmet medical needs. With a strong emphasis on research and development, Curanex is strategically positioned to advance its clinical programs and contribute meaningfully to the pharmaceutical industry.

LPTX
+368.57%
$2.05
CANF
+5.00%
$0.38
ASBP
+15.77%
$0.10
NVDA
-2.80%
$181.36
ONDS
+25.33%
$7.84
PLUG
+2.63%
$2.14
WTO
-8.00%
$0.02
LOBO
+27.77%
$0.50
VHAI
-33.33%
$0.00
CHR
+0.63%
$0.04
ASST
+7.69%
$1.12
CMND
-21.84%
$0.21
OLMA
+136.38%
$20.14
TSLA
-1.87%
$401.25
F
+1.08%
$13.02
AXDX
-61.36%
$0.03
PFE
+1.47%
$25.45
SOFI
-2.95%
$26.24
BITF
+2.99%
$2.75
QUBT
+7.30%
$12.34
INTC
-1.09%
$34.33
AMZN
-4.43%
$222.55
WBD
+4.17%
$23.69
NIO
-1.64%
$5.98
GRAB
-0.18%
$5.32
DNN
-0.41%
$2.38
ACHR
+2.56%
$7.61
ETHD
-8.08%
$5.23
SNAP
+0.85%
$8.25
PLTR
-2.28%
$167.33
WULF
+8.59%
$12.00
BMNR
+4.29%
$32.28
ADAP
-15.14%
$0.05
MARA
+3.21%
$11.88
GOOGL
-0.25%
$284.28
CAN
+20.75%
$1.03
NOK
-0.30%
$6.64
AAL
+0.16%
$12.36
AAPL
0.00%
$267.44
AMD
-4.25%
$230.29
CIFR
+1.60%
$14.58
KVUE
-0.06%
$16.23
RGTI
+4.13%
$25.71
NFLX
+3.44%
$114.09
HPE
-1.55%
$20.90
BYND
-3.84%
$1.01
ABEV
-0.39%
$2.53
T
+0.51%
$25.60
TLRY
0.00%
$1.03
RIVN
+0.80%
$14.99
RMBL
+60.50%
$3.21
RIG
+1.22%
$4.13
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
IREN
+3.03%
$48.85
GPUS
+0.84%
$0.24
RR
+3.84%
$3.24
RUBI
-4.22%
$0.16
BAC
+0.31%
$51.64
SRM
+53.27%
$10.30
KXIN
+2.14%
$0.29
BURU
-5.42%
$0.20
CLF
+2.00%
$11.19
MSFT
-2.69%
$493.79
PLTD
+2.29%
$7.12
MU
-5.55%
$228.50
CRWV
-0.57%
$74.90
LFS
+68.39%
$6.50
SOUN
+0.87%
$11.53
APLT
+4.99%
$0.29
QS
+0.15%
$12.97
BTBT
+3.47%
$2.38
EPSM
+91.54%
$2.72
GOOG
-0.22%
$284.96
BBD
-0.55%
$3.60
PCG
-1.10%
$16.15
ONFO
+11.48%
$0.94
BTG
0.00%
$3.99
HOOD
-1.44%
$114.30
BTE
+3.97%
$3.14
WLGS
-5.57%
$0.04
MRK
+3.84%
$96.43
SMCI
+2.34%
$34.90
MTSR
-0.35%
$70.50
TWOH
+4.16%
$0.00
QBTS
+0.43%
$22.93
IONZ
-5.35%
$4.77
AMCR
+0.11%
$8.46
DVLT
-6.16%
$1.75
APLD
-0.41%
$22.84
EOSE
+3.69%
$13.48
HIMS
+1.91%
$36.26
HBAN
+0.32%
$15.35
VALE
0.00%
$12.17
CGTL
-11.32%
$0.71
NBIS
+5.30%
$90.54
CLSK
+1.88%
$10.81
PLTZ
+4.50%
$7.42
CSCO
-0.52%
$77.37
RXRX
+0.97%
$4.16
LPTX
+368.57%
$2.05
CANF
+5.00%
$0.38
ASBP
+15.77%
$0.10
NVDA
-2.80%
$181.36
ONDS
+25.33%
$7.84
PLUG
+2.63%
$2.14
WTO
-8.00%
$0.02
LOBO
+27.77%
$0.50
VHAI
-33.33%
$0.00
CHR
+0.63%
$0.04
ASST
+7.69%
$1.12
CMND
-21.84%
$0.21
OLMA
+136.38%
$20.14
TSLA
-1.87%
$401.25
F
+1.08%
$13.02
AXDX
-61.36%
$0.03
PFE
+1.47%
$25.45
SOFI
-2.95%
$26.24
BITF
+2.99%
$2.75
QUBT
+7.30%
$12.34
INTC
-1.09%
$34.33
AMZN
-4.43%
$222.55
WBD
+4.17%
$23.69
NIO
-1.64%
$5.98
GRAB
-0.18%
$5.32
DNN
-0.41%
$2.38
ACHR
+2.56%
$7.61
ETHD
-8.08%
$5.23
SNAP
+0.85%
$8.25
PLTR
-2.28%
$167.33
WULF
+8.59%
$12.00
BMNR
+4.29%
$32.28
ADAP
-15.14%
$0.05
MARA
+3.21%
$11.88
GOOGL
-0.25%
$284.28
CAN
+20.75%
$1.03
NOK
-0.30%
$6.64
AAL
+0.16%
$12.36
AAPL
0.00%
$267.44
AMD
-4.25%
$230.29
CIFR
+1.60%
$14.58
KVUE
-0.06%
$16.23
RGTI
+4.13%
$25.71
NFLX
+3.44%
$114.09
HPE
-1.55%
$20.90
BYND
-3.84%
$1.01
ABEV
-0.39%
$2.53
T
+0.51%
$25.60
TLRY
0.00%
$1.03
RIVN
+0.80%
$14.99
RMBL
+60.50%
$3.21
RIG
+1.22%
$4.13
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
IREN
+3.03%
$48.85
GPUS
+0.84%
$0.24
RR
+3.84%
$3.24
RUBI
-4.22%
$0.16
BAC
+0.31%
$51.64
SRM
+53.27%
$10.30
KXIN
+2.14%
$0.29
BURU
-5.42%
$0.20
CLF
+2.00%
$11.19
MSFT
-2.69%
$493.79
PLTD
+2.29%
$7.12
MU
-5.55%
$228.50
CRWV
-0.57%
$74.90
LFS
+68.39%
$6.50
SOUN
+0.87%
$11.53
APLT
+4.99%
$0.29
QS
+0.15%
$12.97
BTBT
+3.47%
$2.38
EPSM
+91.54%
$2.72
GOOG
-0.22%
$284.96
BBD
-0.55%
$3.60
PCG
-1.10%
$16.15
ONFO
+11.48%
$0.94
BTG
0.00%
$3.99
HOOD
-1.44%
$114.30
BTE
+3.97%
$3.14
WLGS
-5.57%
$0.04
MRK
+3.84%
$96.43
SMCI
+2.34%
$34.90
MTSR
-0.35%
$70.50
TWOH
+4.16%
$0.00
QBTS
+0.43%
$22.93
IONZ
-5.35%
$4.77
AMCR
+0.11%
$8.46
DVLT
-6.16%
$1.75
APLD
-0.41%
$22.84
EOSE
+3.69%
$13.48
HIMS
+1.91%
$36.26
HBAN
+0.32%
$15.35
VALE
0.00%
$12.17
CGTL
-11.32%
$0.71
NBIS
+5.30%
$90.54
CLSK
+1.88%
$10.81
PLTZ
+4.50%
$7.42
CSCO
-0.52%
$77.37
RXRX
+0.97%
$4.16
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.